Perioperative Durvalumab Plus Chemotherapy Improves Survival in Resectable Gastric and Gastroesophageal Junction Cancer, The Lancet Reports

Final overall survival analysis from the global, randomized Phase 3 MATTERHORN clinical trial, published in The Lancet, indicates that adding perioperative durvalumab to standard chemotherapy reduced the risk of death by 22% in patients with localized, resectable gastric or gastroesophageal junction cancer. These findings support this new perioperative combination as a new standard treatment option for this patient population.

Context

The MATTERHORN trial is a global, randomized Phase 3 clinical trial assessing the efficacy of durvalumab, an immunotherapy drug, in combination with standard chemotherapy. Gastric and gastroesophageal junction cancers are known for their poor prognosis, particularly in advanced stages. Previous treatments have had limited success, making new options critical for patient outcomes.

Why it matters

The study highlights a significant advancement in the treatment of localized gastric and gastroesophageal junction cancer. By demonstrating a 22% reduction in the risk of death, the findings could lead to improved survival rates for patients. This new treatment approach may change clinical practices and guidelines for managing these cancers.

Implications

Patients with localized gastric and gastroesophageal junction cancer may benefit from improved survival rates with the new treatment. This could lead to a shift in treatment protocols and increased access to effective therapies. Additionally, pharmaceutical companies may see increased interest in developing similar combination therapies for other types of cancer.

What to watch

Healthcare providers may begin to adopt this new treatment regimen as standard practice following the publication of the study. Regulatory bodies may also evaluate the findings for potential approval of this combination therapy. Ongoing research may focus on long-term outcomes and side effects associated with this treatment.